Sab Biotherapeutics Inc. Class WSABSWPreferred / convertible
13F holders, Q1 2024 (March 31)12holders
$0.04avg. 13F price*
At the end of Q1 2024, 12 institutions reported holding Sab Biotherapeutics Inc. Class W (SABSW) in their 13F filings. The largest holders were LMR Partners LLP ($21K), Shaolin Capital Management LLC ($11K) and Morgan Stanley ($4K).
- Company
- Sab Biotherapeutics Inc. Class W
- CUSIP
- 78397T111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $489 |
| Exits | 1 | $872 |
Ownership 12 holders
| LMR Partners LLP | — | No change | 539,588 | $21K |
| Shaolin Capital Management LLC | — | Reduce -21.2% | 292,965 | $11K |
| Morgan Stanley | — | No change | 148,939 | $4K |
| Yakira Capital Management, Inc. | — | No change | 108,485 | $4K |
| Walleye Capital LLC | — | No change | 23,258 | $907 |
| Wolverine Asset Management LLC | — | Reduce -0.1% | 22,783 | $888 |
| Walleye Trading LLC | — | No change | 15,505 | $605 |
| Susquehanna International Group, LLP | — | New | 12,366 | $482 |
| NewEdge Advisors, LLC | — | No change | 1,072 | $42 |
| Clear Street LLC | — | New | 100 | $4 |
| Bank of America Corp. | — | New | 100 | $3 |
| Tower Research Capital LLC (TRC) | — | No change | 48 | $2 |
"% of holder's portfolio" is SABSW's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. Class W the manager owns.